Advertisement

Topics

Poniard Pharmaceuticals Company Profile

02:52 EST 16th December 2018 | BioPortfolio

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. We are currently focusing our development efforts on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. We are studying picoplatin in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. Our business strategy is to form partnerships to support and expand our clinical programs and commercial opportunities and to build a diverse portfolio of oncology product candidates. As part of this strategy, we are collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors as therapeutic agents to treat cancer. Poniard is headquartered in South San Francisco. We are traded on the NASDAQ Capital Market under the symbol PARD.

Location

7000 Shoreline Court
Suite 270
South San Francisco
CA
94080
United States of America

Contact

Phone: 650-583-3774
Fax: 650-583-3789
Email: info@poniard.com


News Articles [316 Associated News Articles listed on BioPortfolio]

PTV News: Nov 17, 2009

Top stories on November 17th, 2009: Glaxo's US$ 500M anti-smoking vaccine deal FDA delays approval of Genzyme's Pompe drug Share crash: Poniard pays the price of Phase III failure Action Shares F...

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hemat...

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmac...

GW Pharmaceuticals plc: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescr...

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Neuren Pharmaceuticals (ASX:NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercializ...

Checkmate Pharmaceuticals Appoints Barry Labinger President & CEO

Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, whe...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA

MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company foc.....

Nuvo Pharmaceuticals to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals

NewsUpon closing of the Proposed Transaction, Nuvo would pay Aralez $110 million in cash,

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [128 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

Clinical Trials [228 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1340 Associated Companies listed on BioPortfolio]

Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. We...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Poniard Pharmaceuticals" on BioPortfolio

We have published hundreds of Poniard Pharmaceuticals news stories on BioPortfolio along with dozens of Poniard Pharmaceuticals Clinical Trials and PubMed Articles about Poniard Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Poniard Pharmaceuticals Companies in our database. You can also find out about relevant Poniard Pharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record